The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting

References

• Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12:354 - 62; PMID: 16489633
   PubMed Web of Science ®Google Scholar
• Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y, Sugimachi K. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 2000; 87:353 - 7; http://dx.doi.org/10.1046/j.1365-2168.2000.01358.x; PMID: 10718807
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11 - 20; http://dx.doi.org/10.1056/NEJMoa055531; PMID: 16822992
   PubMed Web of Science ®Google Scholar
• Moriguchi S, Maehara Y, Korenaga D, Sugimachi K, Nose Y. Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer. Surg Oncol 1992; 1:341 - 6; http://dx.doi.org/10.1016/0960-7404(92)90034-I; PMID: 1341269
   PubMedGoogle Scholar
• Roviello F, Marrelli D, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, De Stefano A, Italian Research Group for Gastric Cancer. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg 2003; 90:1113 - 9; http://dx.doi.org/10.1002/bjs.4164; PMID: 12945079
   PubMed Web of Science ®Google Scholar
• Wu CW, Lo SS, Shen KH, Hsieh MC, Chen JH, Chiang JH, Lin HJ, Li AF, Lui WY. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg 2003; 27:153 - 8; PMID: 12616428
   PubMed Web of Science ®Google Scholar
• Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000; 87:236 - 42; http://dx.doi.org/10.1046/j.1365-2168.2000.01360.x; PMID: 10671934
   PubMed Web of Science ®Google Scholar
• Okines AF, Cunningham D. Multimodality treatment for localized gastro-oesophageal cancer. Ann Oncol 2010; 21:Suppl 7 vii286 - 93; http://dx.doi.org/10.1093/annonc/mdq282; PMID: 20943630
   PubMedGoogle Scholar
• Setälä LP, Kosma VM, Marin S, Lipponen PK, Eskelinen MJ, Syrjänen KJ, Alhava EM. Prognostic factors in gastric cancer: the value of vascular invasion, mitotic rate and lymphoplasmacytic infiltration. Br J Cancer 1996; 74:766 - 72; http://dx.doi.org/10.1038/bjc.1996.434; PMID: 8795580
   PubMed Web of Science ®Google Scholar
• Kamoi D, Ishii H, Takahashi H, Aoyama T, Toriyama T, Tanaka M, Kawamura Y, Kawashima K, Yoshikawa D, Amano T, et al. Sirolimus- vs. paclitaxel-eluting stent to coronary intervention in dialysis patients. Int J Cardiol 2013; 165:533 - 6; http://dx.doi.org/10.1016/j.ijcard.2011.09.078; PMID: 22000423
   PubMed Web of Science ®Google Scholar
• Lee HE, Chae SW, Lee YJ, Kim MA, Lee HS, Lee BL, Kim WH. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer 2008; 99:1704 - 11; http://dx.doi.org/10.1038/sj.bjc.6604738; PMID: 18941457
   PubMed Web of Science ®Google Scholar
• Gronau S, Schmitt M, Reinhardt P, Wiesneth M, Riechelmann H. [T-cells activated with a trifunctional bi-specific antibody in head and neck cancer]. Laryngorhinootologie 2005; 84:822 - 8; http://dx.doi.org/10.1055/s-2005-861448; PMID: 16358189
   PubMed Web of Science ®Google Scholar
• Riesenberg R, Buchner A, Pohla H, Lindhofer H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). J Histochem Cytochem 2001; 49:911 - 7; http://dx.doi.org/10.1177/002215540104900711; PMID: 11410615
   PubMed Web of Science ®Google Scholar
• Gronau SS, Schmitt M, Thess B, Reinhardt P, Wiesneth M, Schmitt A, Riechelmann H. Trifunctional bispecific antibody-induced tumor cell lysis of squamous cell carcinomas of the upper aerodigestive tract. Head Neck 2005; 27:376 - 82; http://dx.doi.org/10.1002/hed.20170; PMID: 15818557
   PubMed Web of Science ®Google Scholar
• Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999; 163:1246 - 52; PMID: 10415020
   PubMed Web of Science ®Google Scholar
• Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001; 98:2526 - 34; http://dx.doi.org/10.1182/blood.V98.8.2526; PMID: 11588051
   PubMed Web of Science ®Google Scholar
• Schmitt M, Schmitt A, Reinhardt P, Thess B, Manfras B, Lindhofer H, Riechelmann H, Wiesneth M, Gronau S. Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Int J Oncol 2004; 25:841 - 8; PMID: 15375531
   PubMed Web of Science ®Google Scholar
• Zeidler R, Mysliwietz J, Csánady M, Walz A, Ziegler I, Schmitt B, Wollenberg B, Lindhofer H. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000; 83:261 - 6; PMID: 10901380
   PubMed Web of Science ®Google Scholar
• Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 2010; 127:2209 - 21; http://dx.doi.org/10.1002/ijc.25423; PMID: 20473913
   PubMed Web of Science ®Google Scholar
• Heiss MM, Ströhlein MA, Jäger M, Kimmig R, Burges A, Schoberth A, Jauch KW, Schildberg FW, Lindhofer H. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005; 117:435 - 43; http://dx.doi.org/10.1002/ijc.21165; PMID: 15906359
   PubMed Web of Science ®Google Scholar
• Burges A, Wimberger P, Kümper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res 2007; 13:3899 - 905; http://dx.doi.org/10.1158/1078-0432.CCR-06-2769; PMID: 17606723
   PubMed Web of Science ®Google Scholar
• Jäger M, Schoberth A, Ruf P, Hess J, Hennig M, Schmalfeldt B, Wimberger P, Ströhlein M, Theissen B, Heiss MM, et al. Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3). Cancer Res 2012; 72:24 - 32; http://dx.doi.org/10.1158/0008-5472.CAN-11-2235; PMID: 22044753
   PubMed Web of Science ®Google Scholar
• Kodera Y, Yamamura Y, Shimizu Y, Torii A, Hirai T, Yasui K, Morimoto T, Kato T. Peritoneal washing cytology: prognostic value of positive findings in patients with gastric carcinoma undergoing a potentially curative resection. J Surg Oncol 1999; 72:60 - 4, discussion 64-5; http://dx.doi.org/10.1002/(SICI)1096-9098(199910)72:2<60::AID-JSO3>3.0.CO;2-1; PMID: 10518099
   PubMed Web of Science ®Google Scholar
• Kodera Y, Nakanishi H, Ito S, Yamamura Y, Fujiwara M, Koike M, Hibi K, Ito K, Tatematsu M, Nakao A. Prognostic significance of intraperitoneal cancer cells in gastric carcinoma: detection of cytokeratin 20 mRNA in peritoneal washes, in addition to detection of carcinoembryonic antigen. Gastric Cancer 2005; 8:142 - 8; http://dx.doi.org/10.1007/s10120-005-0318-7; PMID: 16086116
   PubMedGoogle Scholar
• Kodera Y, Nakanishi H, Ito S, Mochizuki Y, Ohashi N, Yamamura Y, Fujiwara M, Koike M, Tatematsu M, Nakao A. Prognostic significance of intraperitoneal cancer cells in gastric carcinoma: analysis of real time reverse transcriptase-polymerase chain reaction after 5 years of followup. J Am Coll Surg 2006; 202:231 - 6; http://dx.doi.org/10.1016/j.jamcollsurg.2005.09.008; PMID: 16427547
   PubMed Web of Science ®Google Scholar
• Shi C, Yang B, Chen Q, Yang J, Fan N. Retrospective analysis of adjuvant intraperitoneal chemotherapy effect prognosis of resectable gastric cancer. Oncology 2011; 80:289 - 95; http://dx.doi.org/10.1159/000329075; PMID: 21778768
   PubMed Web of Science ®Google Scholar
• Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006; 94:128 - 35; http://dx.doi.org/10.1038/sj.bjc.6602924; PMID: 16404366
   PubMed Web of Science ®Google Scholar
• Kondo T, Ito F, Nakazawa H, Horita S, Osaka Y, Toma H. High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. J Urol 2004; 171:2171 - 5; http://dx.doi.org/10.1097/01.ju.0000127726.25609.87; PMID: 15126779
   PubMed Web of Science ®Google Scholar
• Bonecchi R, Bianchi G, Bordignon PP, D’Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998; 187:129 - 34; http://dx.doi.org/10.1084/jem.187.1.129; PMID: 9419219
   PubMed Web of Science ®Google Scholar
• Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6:295 - 307; http://dx.doi.org/10.1038/nri1806; PMID: 16557261
   PubMed Web of Science ®Google Scholar
• Berntsen A, Brimnes MK, thor Straten P, Svane IM. Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2. J Immunother 2010; 33:425 - 34; http://dx.doi.org/10.1097/CJI.0b013e3181cd870f; PMID: 20386464
   PubMed Web of Science ®Google Scholar
• Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, Hori S, Maeda M, Onodera M, Uchiyama T, Fujii S, et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 2004; 16:1643 - 56; http://dx.doi.org/10.1093/intimm/dxh165; PMID: 15466453
   PubMed Web of Science ®Google Scholar
• Salgado FJ, Lojo J, Fernández-Alonso CM, Viñuela J, Cordero OJ, Nogueira M. Interleukin-dependent modulation of HLA-DR expression on CD4and CD8 activated T cells. Immunol Cell Biol 2002; 80:138 - 47; http://dx.doi.org/10.1046/j.1440-1711.2002.01055.x; PMID: 11940114
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005; 175:6169 - 76; PMID: 16237114
   PubMed Web of Science ®Google Scholar
• Speiser DE, Liénard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115:739 - 46; PMID: 15696196
   PubMed Web of Science ®Google Scholar
• Appay V, Jandus C, Voelter V, Reynard S, Coupland SE, Rimoldi D, Lienard D, Guillaume P, Krieg AM, Cerottini JC, et al. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol 2006; 177:1670 - 8; PMID: 16849476
   PubMed Web of Science ®Google Scholar
• Rezvani K, Yong AS, Mielke S, Jafarpour B, Savani BN, Le RQ, Eniafe R, Musse L, Boss C, Kurlander R, et al. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica 2011; 96:432 - 40; http://dx.doi.org/10.3324/haematol.2010.031674; PMID: 21134985
   PubMed Web of Science ®Google Scholar
• Aoyama T, Yoshikawa T, Hayashi T, Kuwabara H, Mikayama Y, Ogata T, Cho H, Tsuburaya A, Rino Y, Masuda M. [S-1/krestin immunochemotherapy for patients with advanced gastric cancer]. Gan To Kagaku Ryoho 2011; 38:1921 - 3; PMID: 22202239
   PubMedGoogle Scholar
• Hirschhaeuser F, Walenta S, Mueller-Klieser W. Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action. Cancer Immunol Immunother 2010; 59:1675 - 84; http://dx.doi.org/10.1007/s00262-010-0894-1; PMID: 20652245
   PubMed Web of Science ®Google Scholar
• Dettmar K, Seitz-Merwald I, Lindemann C, Schroeder P, Seimetz D, Atz J. Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo. Clin Transl Oncol 2012; 14:376 - 81; http://dx.doi.org/10.1007/s12094-012-0811-5; PMID: 22551544
   PubMed Web of Science ®Google Scholar
• Nishimura T, Nakui M, Sato M, Iwakabe K, Kitamura H, Sekimoto M, Ohta A, Koda T, Nishimura S. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 2000; 46:Suppl S52 - 61; http://dx.doi.org/10.1007/PL00014051; PMID: 10950149
   PubMed Web of Science ®Google Scholar
• Berghuis D, Santos SJ, Baelde HJ, Taminiau AH, Egeler RM, Schilham MW, Hogendoorn PC, Lankester AC. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. J Pathol 2011; 223:347 - 57; http://dx.doi.org/10.1002/path.2819; PMID: 21171080
   PubMed Web of Science ®Google Scholar
• Chu Y, Yang X, Xu W, Wang Y, Guo Q, Xiong S. In situ expression of IFN-gamma-inducible T cell alpha chemoattractant in breast cancer mounts an enhanced specific anti-tumor immunity which leads to tumor regression. Cancer Immunol Immunother 2007; 56:1539 - 49; http://dx.doi.org/10.1007/s00262-007-0296-1; PMID: 17659370
   PubMed Web of Science ®Google Scholar
• Hong M, Puaux AL, Huang C, Loumagne L, Tow C, Mackay C, Kato M, Prévost-Blondel A, Avril MF, Nardin A, et al. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res 2011; 71:6997 - 7009; http://dx.doi.org/10.1158/0008-5472.CAN-11-1466; PMID: 21948969
   PubMed Web of Science ®Google Scholar
• Musha H, Ohtani H, Mizoi T, Kinouchi M, Nakayama T, Shiiba K, Miyagawa K, Nagura H, Yoshie O, Sasaki I. Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int J Cancer 2005; 116:949 - 56; http://dx.doi.org/10.1002/ijc.21135; PMID: 15856455
   PubMed Web of Science ®Google Scholar
• Pan J, Burdick MD, Belperio JA, Xue YY, Gerard C, Sharma S, Dubinett SM, Strieter RM. CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J Immunol 2006; 176:1456 - 64; PMID: 16424173
   PubMed Web of Science ®Google Scholar
• Pertl U, Luster AD, Varki NM, Homann D, Gaedicke G, Reisfeld RA, Lode HN. IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J Immunol 2001; 166:6944 - 51; PMID: 11359856
   PubMed Web of Science ®Google Scholar
• Mullins IM, Slingluff CL, Lee JK, Garbee CF, Shu J, Anderson SG, Mayer ME, Knaus WA, Mullins DW. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res 2004; 64:7697 - 701; http://dx.doi.org/10.1158/0008-5472.CAN-04-2059; PMID: 15520172
   PubMed Web of Science ®Google Scholar
• Ziegler A, Heidenreich R, Braumüller H, Wolburg H, Weidemann S, Mocikat R, Röcken M. EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion. Blood 2009; 113:3494 - 502; http://dx.doi.org/10.1182/blood-2008-08-175109; PMID: 19188665
   PubMed Web of Science ®Google Scholar
• Atanackovic D, Matsuo M, Ritter E, Mazzara G, Ritter G, Jäger E, Knuth A, Old LJ, Gnjatic S. Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC. J Immunol Methods 2003; 278:57 - 66; http://dx.doi.org/10.1016/S0022-1759(03)00209-6; PMID: 12957396
   PubMed Web of Science ®Google Scholar